Previous 10 | Next 10 |
home / stock / lly / lly articles
Novo Nordisk A/S (NYSE:NVO) has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic (semaglutide) will n...
Costco Wholesale Corporation (NASDAQ:COST) has launched a weight management program to help its members in their weight loss journey. The program w...
AstraZeneca Plc’s (NASDAQ:AZN) Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a s...
Verve Therapeutics Inc (NASDAQ:VERV) announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in pa...
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried abou...
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried abou...
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 5 years by 30.75% on an annualized basis producing an average annual return o...
U.S. commodity exporters and pharmaceutical companies are among the top traders, with Japan casting a cautious eye toward the foreign exchange mark...
Monday, Biohaven’s (NYSE:BHVN) CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...